International Agreements

Nordic EMBL Partnership for Molecular Medicine Extended

Rector Thomas Wilhelmsson and Professor Olli Kallioniemi signed the Framework Agreement of the Nordic EMBL Partnership for Molecular Medicine between EMBL, DANDRITE/Aarhus University, FIMM/University of Helsinki, MIMS/Umeå University and NCMM/University of Oslo in March 2013 in Aarhus, Denmark. The Agreement was signed for the next ten-year period (2013—2022). Collaboration between EMBL and the Nordic nodes has extended to all levels, from doctoral students’ joint activities, research collaboration to collaboration among the administrative staff.

Prof. Thomas Wilhelmsson, Rector of University of Helsinki, Prof. Lena Gustafsson, Vice-Chancellor of Umeå University, Prof. Lauritz B. Holm-Nielsen, Rector of Aarhus University and Prof. Ole Petter Ottersen, Rector of University of Oslo.

Prof. Olli Kallioniemi signing the Framework Agreement.


Other Nordic EMBL Partnership activities

The 4th Nordic Molecular Medicine Network meeting was held at Oslo Science Park on 17-19 September 2013.


Young scientists from institutes in the Nordic EMBL Partnership for Molecular Medicine visit Heidelberg in June 2013. EMBL is credited for the photo.


FIMM joined the EU-LIFE (European Life Sciences Institutes for Excellence) network comprising of nine top biomedical research institutes from Europe, including, e.g. Centre of Genomic Regulation (CRG, Barcelona, Spain; EMBL Partnership). The Consortium Agreement was signed in December 2013. The purpose of the network is to support and strengthen European research excellence, and its impact on health systems and society. Partners discuss latest developments in European science policy and produce documents for policy makers and stakeholders in life sciences.  In addition, several working groups define and share best practices, as well as design joint activities on topics of common interest, such as technology transfer, translational research, research training and science communication. EU-LIFE will work closely with EU commission, European Research Council (ERC), Innovative Medicines Initiative (IMI) and other European organization and will help to ensure best practices are distributed in Europe between research institutions.


International Agreements